Connect with us


The world’s first CBD facial comes to the UK



As the world’s first industry-endorsed CBD facial and cosmeceutical skincare range launches in the UK, Cannabis Health speaks to those behind it.

Now widely recognised for its anti-inflammatory and antioxidant properties, cannabis is changing the face of the beauty industry.

As the latest go-to ingredient for skin and beauty brands, an influx of CBD-infused products have hit the shelves in recent years, with an industry report published earlier this year suggesting that the CBD skincare market is projected to generate £734m in annual sales by 2024.

Meanwhile leading doctors have touted the potential of cannabis to treat rare and challenging skin conditions, such as atopic eczema, allergic contact dermatitis and psoriasis, as the UK’s first medical cannabis dermatology service launched at the Sapphire Clinic in London in September.

But until now, no one has brought the two together.

The Grass Roots Facial, the world’s first CIBTAC (Confederation of International Beauty Therapy and Cosmetology) endorsed CBD facial procedure – using a full range of cosmeceutical CBD skincare products – is coming to the UK from October.

Created by global beauty training provider SkinTres, founders Jo Minchin, Lyndsey Price and Zoe Wilkinson saw the potential of the cannabinoid and set out to create a dynamic, results-driven and relaxing facial – but quickly realised that they would need to develop their own skincare range too.

SkinTres founders (from left) Lyndsey Price, Jo Minchin and Zoe Wilkinson

“Other brands were doing a nod to CBD, with products containing 100mg or less, but nobody was doing the cosmeceutical skincare that most women in their 30s and 40s now are using,” said Jo Minchin, co-founder of SkinTres, Grass Roots Facial and Grass Roots Skin.

“If you wanted to incorporate CBD into your skincare, you’d have to buy a CBD oil and use this alongside your existing skincare routine –  it was adding too much and is also quite expensive.”

She added: “We saw this gap in the market and it felt like a perfect opportunity to incorporate CBD into our own range of cosmeceutical skincare, along with retinols, Vitamin C and hyaluronic acid.”

There are initially seven products in the Grass Roots Skin range from the AHA Cleansing Wash and AHA Skin Tonic at £28.99, to the Skin Drench Super Serum, containing 15 percent vitamin C, hyaluronic acid and 300mg of CBD isolate – which at £54.99 has been described as the brand’s ‘superhero’.

Also in the range are a 1% Retinol Repair Cream, Retinol Eye Refiner, Super Glow Miracle Oil and Super Shield SPF50, all of which have been third party tested, are vegan-friendly, cruelty-free and unisex.

The products go hand in hand with the Grass Roots Facial, a five step, in-salon treatment which can be personalised to suit any skin type and is designed to give instant results.

It starts with dermaplaning, where a fine surgical blade is passed back and forth along the top layer of the skin to remove dead skin cells and allows the skin to absorb the ingredients of the products.

A special CBD-infused oil is used to boost the anti-inflammatory effect of lymphatic drainage, a therapeutic massage treatment, which uses light pressure and rhythmic strokes to increase the flow of lymph and reduce toxins in the body.

LED light therapy then uses different wavelengths of light to target certain conditions including acne, rosacea, sensitive, pigmented and ageing skin.

“We’ve designed the facial so that anyone can benefit from it, by creating different processes within it that can be adapted for any skin condition,” explained co-founder Zoe Wilkinson from the Skin Tres salon and training centre in Oxfordshire.

“For example, if someone has active acne we wouldn’t do the dermaplaning part of the facial, but we could do more lymphatic drainage and spend more time with the LED light.

“The idea is that the skin will absorb the products better and the end result will be an instant glow, as well as reducing inflammation and redness, but also a really relaxing facial.”

At the moment the Grass Roots Facial and skincare range will only be available at salons where therapists have completed a Skin Tres CIBTAC approved course.

From October 2020 training will be provided at the SkinTres training centres in Witney in Oxfordshire and Marple in Cheshire, but the aim is to roll it out to salons across the UK.

“An important part of our message is educating people about CBD, so a big part of the process is training and teaching therapists to be knowledgeable about the products, so they can teach their clients the benefits of that and help to educate people,” said Jo.

“A lot of people are still afraid of CBD and don’t really understand it, but the more we people can educate about it, the more people will try it.

“In five years, everybody will have probably tried something with a bit of CBD in.”

And this could be groundbreaking in how common skin conditions are managed.

Zoe added: “The biggest use for CBD is in skin conditions such as eczema, acne and psoriasis, because of its anti-inflammatory and antibacterial properties.

“Doctors often prescribe strong ointments for these conditions, so if people can treat them with something natural like CBD, before going down the medical route, that could massively change how we use skincare.”

For more information visit and
















Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


Weekend digest: Six big stories from the cannabis world you might have missed



Another week, another rollercoaster in the fast-moving world of cannabis.

At Cannabis Health, our in depth coverage of the ongoing growth of cannabis as a medical and wellness product continues

Meanwhile, over at Cannabis Wealth, we’ve been following all the big industry and policy news in a week which has seen some important developments..

Been busy and want to get caught up in a hurry?

Here are the six things you need to read to stay in the loop this week.

1. Products pulled from shelves

Two batches of medical cannabis products have been recalled by regulators as investigations are carried out, following reports they may be contaminated with mould.

Medical cannabis pharmacy, Dispensary Green and the Medicines and Healthcare products Regulatory Agency (MHRA) have issued a ‘precautionary’ product recall since being made aware of ‘defects’ in patient’s medication.

Concerns were initially raised after a number of medical cannabis patients spotted what they believed to be mould spores in their prescriptions.

Full story here.

2. NFL turns to medical cannabis

The National Football League (NFL) in America is providing $1 million in funding for research into pain management and cannabinoids.

The NFL is funding research into medical cannabis.

The pain management committee of the NFL and the NFL Players Association announced it would stump up the funding on Tuesday 8 June.

According to the organisation’s news platform, the move is the next step in a shifting attitude towards players who use medicinal cannabis to manage pain from injuries.

You can read more here.

3. More medical cannabis evidence

Researchers have found that the cannabinoids CBD and CBG, when used in combination, are beneficial for treating inflammation in the lungs.

Scientists at King’s College London, working in collaboration with Sativa Wellness Group have published the first results from a study into the impact of cannabinoids on respiratory diseases.

It aimed to investigate the anti-inflammatory effects of the two non-psychotropic cannabinoids alone and in combination, in a model of pulmonary inflammation.

Full details here.

4. Germany to vote for reform?

Germany’s national election on September 26 could be a landmark moment for Europe’s cannabis industry.

As Chancellor Angela Merkel prepares to leave the stage, the European Union’s most influential country looks destined for a political shakeup.

Annalena Baerbock could become Germany’s first pro-drug reform Chancellor.

It could mark a huge moment for the cannabis industry as Germany’s parliament might swing in favour of legislation.

Here’s everything you need to know about it.

5. Adapt or fail

The pro-drug reform lobby must accept it has failed and change to push its agenda ahead, leading experts have warned.

Speaking at a Global Cannabis Intelligence event about the state of advocacy in the UK, three leading policy advocates set out how they think greater access can be achieved.

The discussion comes week after the 50-year anniversary of the passage of the The Misuse of Drugs Act.

Read the full story here.

6. Isle of Man steps up

The Isle of Man government has declared it is open for business to the medical cannabis industry.

In a big to create 250 new jobs and generate £3m a year for the island, policymakers want it to become ‘a world-leading exporter’.

Applications are now open for licences to produce and distribute treatments on the island, as well as to use it as an export base.

Full details here.

Continue Reading


New tracking app launches for UK medical cannabis patients

Through the app patients will be able to monitor their own symptoms and medication usage



The free health monitoring app is already being used elsewhere in the world.

UK medical cannabis suppliers Grow Pharma have teamed up with an Australian tech firm to launch a new app for patients.

The partnership with OnTracka will see them launch Calyx, a free health monitoring app already being used elsewhere in the world.

Users will be able to monitor their own symptoms and medication usage, speak securely with their doctor and contribute to gathering evidence about the use of medical cannabis.

The app will also be available in Ireland and the Channel Islands after successful launches in Australia, the US and South America.

Users will be able to monitor their own symptoms and medication usage

Pierre Van Weperen, CEO of Grow Pharma said: “Grow Pharma is currently fulfilling around a third of all prescriptions for the UK’s medicinal cannabis patients.

“Our prominent role gives us a significant advantage to building data insights into how patients are managing their health.

“This is integral to pave the way towards increasing access for patients in the UK through providing doctors with confidence around the safety and efficacy of these products.

“Using the app will generate important insights to provide real-time evidence to doctors and regulators.”

Grow Pharma hopes the app will help ‘rapidly accelerate an understanding of the safety, quality, and efficacy’ of medical cannabis.

Insights gained via the app will ‘advance the industry forward in the service of patients, shaping future legislation and policy based on patient experiences’ by providing real-world data to regulators.

Grow is in the process of raising £6 million worth of capital via a private funding round expect to be completed later this month.

Continue Reading


Isle of Man launches medical cannabis export sector

The Isle of Man is open for business to the medical cannabis industry.



The move could 250 new jobs and generate £3 million a year for the island

The Isle of Man government has declared it is open for business to the medical cannabis industry.

In a big to create 250 new jobs and generate £3 million a year for the island, policymakers want it to become ‘a world-leading exporter’.

Applications are now open for licences to produce and distribute treatments on the island, as well as to use it as an export base.

The island’s regulator – the Gambling Supervision Commission – has set out conditions for the licensing of high-THC cannabis and hemp.

Enterprise minister Laurence Skelly said: “The growing global medicinal cannabis market provides significant opportunity for economic development in the Isle of Man, and the new regulatory framework and guidance will offer stringent and flexible licensing of a broad range of cannabis products, which ranges from outdoor grown industrial hemp to indoor grown medicinal products.

“The Isle of Man Government has every confidence that the GSC will provide a world class regulatory structure required to regulate this new and complex industry.

The Isle of Man wants to be a major player in Europe’s growing medical cannabis industry.

“I am delighted to welcome licence applications and look forward to attracting quality businesses to the Island, transforming the cannabis export sector into a key contributor to the Isle of Man’s post-Covid economic recovery.”

The self-governing British Crown Dependency, which has a population of 83,000, approved new medical cannabis laws in January.

The island’s parliament – the Tynwald – moved to attract the industry to its shores after a public consultation showed 95 percent of residents were in favour of the policy.

Mark Rutherford, director of policy at the island’s regulator, said: “The GSC already has a sophisticated framework for supervising gambling.

‘We have worked carefully to apply the best of that framework to the risks in the new sector and we have educated ourselves in the technical areas that are new to us.

“What we now have will ensure that all stakeholders will be competent, crime free and capable of building a sector that is safe, trusted and efficient.

“As regulators, we aspire to put our regulatory umbrella above as many consumers as possible so that they can benefit from regulations that are well thought out and properly supervised.

“Years of prohibition mean that the markets in which our licensees will be participating are still in their infancy and still contain many uncertainties.

“To address this situation, it is our aim to ensure that consumers who purchase Isle of Man products will be able to understand exactly what their product contains through accurate labelling and independent testing.

“The GSC recognises there are many stakeholders in this newly created field and intends to extend its ethos of cooperation with other government authorities into its approach to cannabis regulation.”

Continue Reading